These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29358293)

  • 21. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
    Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
    Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
    Tam VH; Ledesma KR; Vo G; Kabbara S; Lim TP; Nikolaou M
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
    Zhuang L; He Y; Xia H; Liu Y; Sy SK; Derendorf H
    J Antimicrob Chemother; 2016 Apr; 71(4):1012-21. PubMed ID: 26702923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
    Khan DD; Friberg LE; Nielsen EI
    J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
    De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
    Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
    Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
    Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
    Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model.
    Katsube T; Yano Y; Yamano Y; Munekage T; Kuroda N; Takano M
    J Pharm Sci; 2008 Sep; 97(9):4108-17. PubMed ID: 18314887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Bowker KE; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
    McGrath BJ; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.